Did Biogen's Kingsley Take Blame For Tecfidera Sales?
This article was originally published in Scrip
The timing of Biogen's Oct. 9 announcement that Tony Kingsley, executive vice president of global commercial operations, is leaving the company came at an unfortunate time – just weeks before third quarter earnings will reveal whether Tecfidera (dimethyl fumarate) sales are growing, stable or sliding.
You may also be interested in...
Private Company Edition: VC deals fell short of the record-breaking level seen in 2018 and financings may slow a bit more in 2020. Also, UPMC and Frazier close new VC funds, and Emendo raises $61m for gene-editing platform.
Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.
Aimovig, Emgality and Ajovy have been on the market for more than a year, but are still far from blockbusters even though millions of patients are eligible for treatment – and at least one new competitor is coming.